New pages
- 15:09, 13 October 2020 Epoetin beta (Recormon) (hist) [36 bytes] Jwarner (talk | contribs) (Created page with "Antianemic agent.")
- 10:57, 13 October 2020 Pegfilgrastim-bmez (Ziextenzo) (hist) [1,379 bytes] Jwarner (talk | contribs) (Created page with "==General information== Class/mechanism: Recombinant human granulocyte colony-stimulating factor (G-CSF), biosimilar of pegfilgrastim. Binds to cell surface receptors on hemat...")
- 21:34, 4 October 2020 Non-small cell lung cancer, Squamous (hist) [49,458 bytes] Jwarner (talk | contribs) (Created page with "{| class="wikitable" style="text-align:center; width:100%;" ! colspan="2" align="center" style="color:white; font-size:125%; background-color:#08519c" |'''Page editor''' ! col...")
- 20:07, 4 October 2020 Non-small cell lung cancer, Nonsquamous (hist) [136,885 bytes] Jwarner (talk | contribs) (Created page with "{| class="wikitable" style="text-align:center; width:100%;" ! colspan="2" align="center" style="color:white; font-size:125%; background-color:#08519c" |'''Page editor''' ! col...")
- 10:31, 30 September 2020 Stilbamidine (hist) [219 bytes] Jwarner (talk | contribs) (Created page with "Of historic interest. Unclear if this drug was ever approved for medical use. ==Diseases for which it was used== *Multiple myeloma Category:Drugs")
- 10:27, 30 September 2020 Urethane (hist) [261 bytes] Jwarner (talk | contribs) (Created page with "Of historic interest. Discontinued as a human drug in 1963 due to carcinogenicity. ==Diseases for which it was used== *Multiple myeloma Category:Drugs Category:Dis...")
- 15:42, 28 September 2020 Decitabine and cedazuridine (Inqovi) (hist) [2,048 bytes] Jwarner (talk | contribs) (Created page with "==Mechanism of action== From the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/cda-inhibitor-e7727-decitabine-combination-agent-astx727 NCI Drug Dictionary...")
- 16:44, 27 September 2020 Pexidartinib (Turalio) (hist) [1,244 bytes] Jwarner (talk | contribs) (Created page with "==Mechanism of action== From the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/pexidartinib NCI Drug Dictionary]: A small-molecule receptor tyrosine kinase...")
- 20:56, 24 September 2020 Alitretinoin (Panretin) (hist) [1,099 bytes] Jwarner (talk | contribs) (Created page with "==Mechanism of action== From the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/alitretinoin NCI Drug Dictionary]: An orally- and topically-active naturally...")
- 19:46, 22 September 2020 Abarelix (Plenaxis) (hist) [1,182 bytes] Jwarner (talk | contribs) (Created page with "==Mechanism of action== From the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/abarelix NCI Drug Dictionary]: A synthetic decapeptide and antagonist of nat...")
- 16:22, 21 September 2020 Lisocabtagene maraleucel (Liso-cel) (hist) [1,630 bytes] Jwarner (talk | contribs) (Created page with "==Mechanism of action== From the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/778386 NCI Drug Dictionary]: A preparation of a defined ratio of CD4+ and CD...")
- 21:23, 8 September 2020 Pralsetinib (Gavreto) (hist) [882 bytes] Jwarner (talk | contribs) (Created page with "==Mechanism of action== From the [NCI Drug Dictionary]: An orally bioavailable selective inhibitor of mutant forms of and fusion products involving the proto-oncogene receptor...")
- 21:27, 2 September 2020 Tepotinib (EMD-1214063) (hist) [1,888 bytes] Jwarner (talk | contribs) (Created page with "==General information== Class/mechanism: C-Met inhibitor. Inappropriate or constitutive activation of the receptor tyrosine kinase c-Met and its signalling pathway is implica...")
- 20:54, 1 September 2020 Azacitidine (Onureg) (hist) [1,686 bytes] Jwarner (talk | contribs) (Created page with "==General information== Class/mechanism: Pyrimidine nucleoside analog of cytidine, causes hypomethylation of DNA and direct cytotoxicity on abnormal hematopoietic cells in the...")
- 19:58, 28 August 2020 Thyroid cancer, RET-positive (hist) [2,585 bytes] Jwarner (talk | contribs) (Created page with "Note: these are regimens tested in biomarker-specific populations, please see the '''main thyroid cancer page''' for other regimens. {| class="wikitable" st...")
- 11:46, 9 August 2020 Belantamab mafodotin (Blenrep) (hist) [1,626 bytes] Jwarner (talk | contribs) (Created page with "==Mechanism of action== From the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-bcma-antibody-drug-conjugate-gsk2857916 NCI Drug Dictionary]: An antibo...")
- 11:31, 30 July 2020 Trimetrexate (Neutrexin) (hist) [1,106 bytes] Jwarner (talk | contribs) (Created page with "==General information== Class/mechanism [https://www.drugbank.ca/drugs/DB01157 from DrugBank]: In vitro studies have shown that trimetrexate is a competitive inhibitor of dihy...")
- 15:32, 25 July 2020 Stub (hist) [26,114 bytes] Jwarner (talk | contribs) (Created page with "Regimens that have not proven to be superior to a standard-of-care comparison and are thus unlikely to be expanded upon. This page is primarily to drive the Ontology. ==T...")
